PubMed Health⌕ Search

Biomedical subjects

F R Macbeth

Publications and source records attributed to F R Macbeth.

26 records · Page 2Linked to original sources
PubMed1982

Epileptic seizures associated with cisplatin administration.

Eighty-one patients with germ cell tumors or ovarian carcinoma were treated over a 4-year period with cisplatin-containing combination chemotherapy. Eight patients (9.8%) experienced epileptic seizures during or within 3 months of this chemotherapy. While a definite causal relationship between the seizures and cisplatin could not be established, we have rarely seen such episodes in relationship to other cytotoxic drugs. A number of possible contributing factors were apparent, including hyponatremia and pretreatment impairment of renal function.

Adult↗
PubMed1981

Problems of the oncology outpatient: role of the liaison health visitor.

A survey by a liaison health visitor of outpatients attending an oncology department has identified and enumerated the principal problems with which she is confronted, and defined her role. The main medical symptoms of concern to the patient at home and needing attention by the liaison health visitor were anorexia, nausea, vomiting, and constipation: inadequate pain control due to poor drug compliance was also common. Other functions of the liaison health visitor include providing nursing aids and prostheses, support for bereaved relatives, and liaison with the community health care team.

Analgesia↗
PubMed1981

Oestrogen-receptor status and endocrine therapy of breast cancer: response rates and status stability.

The concentration of cellular oestrogen receptor (RE) was measured in both the soluble and nuclear-pellet fractions of biopsies from 1,000 breast cancers. Data suggest that functional steroid RE is always in equilibrium between the soluble and nuclear fractions. However, biopsies from only one-third of patients contained detectable amounts of high-affinity RE in both fractions. Thirty patients out of 42 (71%) whose biopsies contained RE in both fractions, showed objective remission after receiving some form of hormonal manipulation as sole treatment. Response rates in the other categories ranged from 9% for those whose biopsies contained no detectable RE to 24% for those who displayed soluble RE alone. The presence of RE in both fractions of primary disease, whereas RE-negativity was maintained during progression from primary to secondary disease. Other aspects of RE status in relation to stage of disease are analysed.

Adult↗
PubMedDate not supplied

A report on a prospective trial of no initial therapy in patients with initial therapy in patients with asymptomatic favourable prognosis non-Hodgkin's lymphoma.

Thirty-one (58 per cent) of a group of fifty-three unselected patients with stage II-IV favourable prognosis non-Hodgkin's lymphoma were regarded as being eligible for a prospective study of no initial therapy. Seventeen of these patients (55 per cent) have required no treatment for periods from 6 + -47 + months, (median 18 months) and fourteen patients have been treated with chemotherapy for progressive disease after a period varying from 3-40 months (median 9.5 months). Selected asymptomatic patients with non-bulky disease may be suitable for no initial therapy. Randomized prospective trials will be needed to test whether survival is affected by delaying therapy.

Adolescent↗
PubMedDate not supplied

Estrogen receptors and antiestrogen therapy in selected human solid tumors.

Tumor biopsies from a range of human cancers not normally thought to be hormone-dependent were assayed for the presence of both cytoplasmic and nuclear estrogen receptors, using strict criteria of specificity and affinity. Of 72 tumor samples assayed, only one had both cytoplasmic and nuclear receptors. However, several others showed the presence of estrogen-binding components with characteristics different from those of the normal human estrogen receptor. Thirty patients with advanced, measurable disease were treated with the antiestrogen tamoxifen. In only 25 of these was the response evaluable, and in each case, the disease progressed. This study suggests that the occurrence of the classic estrogen receptor in human cancers, other than breast and uterine, is rare; this finding is supported by the absence of response of advanced disease to antiestrogen treatment.

Binding, Competitive↗